Related Articles
Clovis Oncology (NASDAQ:CLVS) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $11.34 and last traded at $11.34, with a volume of 1732319 shares trading hands. The stock had previously closed at $12.33.
Several equities analysts recently issued reports on the company. HC Wainwright set a $51.00 price objective on Amarin and gave the company a “buy” rating in a research report on Wednesday, July 3rd. Piper Jaffray Companies decreased their price objective on Clovis Oncology from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Sunday, April 14th. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. JPMorgan Chase & Co. raised ROYAL MAIL PLC/ADR from an “underweight” rating to a “neutral” rating in a research report on Monday, June 3rd. Finally, SunTrust Banks upped their price target on Edison International to $77.00 and gave the stock a “positive” rating in a research report on Monday, April 15th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $27.44.
The company has a current ratio of 4.39, a quick ratio of 4.15 and a debt-to-equity ratio of 8.04. The stock has a 50-day moving average of $14.00. The stock has a market capitalization of $580.46 million, a PE ratio of -1.55 and a beta of 1.91.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.17. Clovis Oncology had a negative return on equity of 196.39% and a negative net margin of 342.54%. The firm had revenue of $33.12 million during the quarter, compared to the consensus estimate of $32.10 million. During the same quarter in the prior year, the firm posted ($1.38) EPS. The business’s revenue was up 78.8% on a year-over-year basis. Equities analysts predict that Clovis Oncology will post -6.76 earnings per share for the current year.
In other news, insider Lindsey Rolfe sold 1,728 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $14.70, for a total transaction of $25,401.60. Following the sale, the insider now owns 23,319 shares in the company, valued at approximately $342,789.30. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 2,452 shares of company stock worth $36,261. Company insiders own 8.30% of the company’s stock.
Several institutional investors have recently made changes to their positions in CLVS. Westfield Capital Management Co. LP bought a new stake in shares of Clovis Oncology during the 1st quarter worth approximately $20,016,000. Redmile Group LLC raised its stake in shares of Clovis Oncology by 12.4% during the 1st quarter. Redmile Group LLC now owns 4,563,929 shares of the biopharmaceutical company’s stock worth $113,277,000 after purchasing an additional 503,400 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in shares of Clovis Oncology by 166.7% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 781,623 shares of the biopharmaceutical company’s stock worth $19,401,000 after purchasing an additional 488,523 shares in the last quarter. Norges Bank bought a new stake in Clovis Oncology in the 4th quarter valued at $8,351,000. Finally, Dimensional Fund Advisors LP bought a new stake in Clovis Oncology in the 4th quarter valued at $5,641,000. Institutional investors own 93.19% of the company’s stock.
Clovis Oncology Company Profile (NASDAQ:CLVS)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Recommended Story: Marijuana Stocks
Receive News & Ratings for Clovis Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Clovis Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.
Source link
